A Randomized, Double-Blind, Placebo-Controlled Phase 1b/2 Study of LY2228820, a p38MAPK Inhibitor, plus Gemcitabine and Carboplatin versus Gemcitabine and Carboplatin for Women with Platinum-Sensitive Ovarian Cancer

Trial Profile

A Randomized, Double-Blind, Placebo-Controlled Phase 1b/2 Study of LY2228820, a p38MAPK Inhibitor, plus Gemcitabine and Carboplatin versus Gemcitabine and Carboplatin for Women with Platinum-Sensitive Ovarian Cancer

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 25 May 2017

At a glance

  • Drugs Ralimetinib (Primary) ; Carboplatin; Gemcitabine
  • Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Eli Lilly
  • Most Recent Events

    • 18 May 2017 Planned primary completion date changed from 1 Feb 2017 to 1 Jul 2017.
    • 01 Mar 2017 Planned End Date changed from 1 Feb 2017 to 1 May 2018.
    • 04 Aug 2016 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top